Select region

Press ReleaseGetinge 2013-12-05

Shareholders representing 70% of outstanding shares in Pulsion have agreed to accept Getinges offer in intended acquisition of Pulsion Medical Systems

As announced yesterday, Getinge has decided to issue a public tender offer to acquire all shares in Pulsion Medical Systems SE (“Pulsion”), listed on the German Stock Exchange (Deutsche Börse). Getinge plans to offer the shareholders in Pulsion to tender their shares for an offer price of 16.90 € per share in cash. The offer will be made by a fully-owned German Getinge subsidiary in accordance with the German Securities and Takeover Act. The offer will be subject to the terms and conditions to be set forth in the offer document.

A shareholder pool led by Forum European Smallcaps GmbH and a number of other shareholders, who together represent approximately 70% of all issued shares and voting rights in Pulsion, have irrevocably undertaken to accept the offer from Getinge.

Dr. Wittek, Chairman of Pulsion’s Board of Directors, has stated that Pulsion considers the offer to be a great opportunity to combine its leading position in hemodynamic monitoring in Europe with the global sales and marketing power of Getinge. After review of the offer document, the Board of Directors of Pulsion will provide a final recommendation to the shareholders.

To read the press announcement from yesterday please visit where, as soon as completed, the offer document also will be published.

För mer information, kontakta:

Ulf Grunander                            
CFO, Getinge Group

Telefon: +46 10 335 55 80       

GETINGE GROUP is a leading global provider of products and systems that contribute to quality enhancement and cost efficiency within healthcare and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management solutions. GETINGE provides solutions for infection control within healthcare and contamination prevention within life sciences. MAQUET specializes in solutions, therapies and products for surgical interventions, interventional cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act.